EASME

TransCure bioServices has developped unique Research & Development (R&D) platforms, called the Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. They provide access to these platforms as a fee-for-service for the pharmaceutical companies, biotechs as well as academic laboratories which profile new drugs targeting immuno-related diseases and novel anti-HIV/AIDS therapies.

FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.

BioMensio Ltd. is a biotechnology company based in Tampere, Finland, established in 2015. It specializes in developing smart multi-analyte handheld detection devices for bio-analytics, providing rapid and on-site detection of various biological targets from a small sample in a single step. The company's offerings include a novel miniaturized micro-array platform that supports the quick development of new bio-screening applications, which are applicable in areas such as saliva testing, food and milk safety, point-of-care diagnostics, and bio-security. BioMensio's technology enables the creation of label-free assays, allowing for the detection of multiple analytes without the need for labeling procedures. Additionally, its Diagnostics-as-a-Service (DXaaS) platform integrates a handheld reader, multianalyte fluid cartridges, and cloud-based analytics, facilitating easier access for original equipment manufacturers (OEM) to develop bio-analysis products and services.

Vetbiobank is a biotech company specializing in veterinary regenerative medicine. The company develops cell and tissue therapies aimed at enhancing animal health and care. In addition to its focus on veterinary applications, Vetbiobank also engages in human cellular and tissue therapies. It supplies veterinarians with clinical-grade cell and tissue products, thereby supporting medical and scientific needs within the veterinary field. Through its innovative approach, Vetbiobank aims to improve outcomes for animals by advancing regenerative medicine techniques.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in photonic biosensor technology. The company leverages patented innovations developed in TNO's Optics department to commercialize rapid, sensitive, and low-cost biosensors and instruments. These advanced biosensors utilize integrated photonics and optical chips containing waveguides that facilitate the transportation of light across multiple sensors. This technology enables real-time, label-free monitoring of biomarkers, allowing for accurate concentration measurements within minutes. Delta Diagnostics aims to enhance research in life sciences and facilitate the development of novel diagnostics through its innovative biosensing solutions.

Chemicare is a biotechnology company established in December 2016, focused on the discovery and development of orphan drugs for patients with calcium-related genetic diseases. The company aims to improve the quality of life for individuals suffering from conditions such as Tubular Aggregate Myopathy, York Platelet Syndrome, and Stormorken Syndrome. Chemicare is dedicated to creating therapies that address the abnormal intracellular calcium levels characteristic of these rare diseases, enabling healthcare professionals to provide effective treatment options for affected patients.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Their strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators,

MycoSolutions AG specializes in developing customized soil additives designed to protect and maintain trees, particularly veteran specimens. Based in St. Gallen, Switzerland, the company offers a range of services including the diagnosis of fungal pathogens, visual tree inspections, hazard assessments, and the development of tailor-made plant growth promoters. MycoSolutions is recognized as a technology leader in the efficient use of mushrooms, leveraging the expertise of its founders and employees to provide environmentally friendly alternatives to conventional wood preservatives and agricultural pesticides. The company's commitment to sustainability aims to reduce the environmental impact of harmful chemicals, while its educational initiatives include training sessions and publications to enhance knowledge in tree care and soil health.

Inflection Biosciences is an early stage, drug development company with a focus on developing innovative small molecule therapeutics that address major unmet needs in cancer. With bases in Dublin and London, the company is dedicated to identifying excellent early stage cancer research from academic institutes and companies around the world. Inflection Biosciences will use its expertise to progress the most promising programs through pre-clinical and early clinical stages, partnering with larger. pharma for later stage clinical development and commercialisation. The company’s founders, including CEO Darren Cunningham and Director of R&D Dr. Michael O’Neill, bring over 60 years of industry experience along with access to a global network of potential partners and service providers.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

Enzymlogic specializes in enzymology and protein science, offering analytical services aimed at enhancing drug discovery and development for the pharmaceutical and biotech industries. The company assists in identifying kinetic profiles during the drug development process, which helps clinicians understand the interactions between drugs and their targets. This insight is crucial for evaluating factors that influence efficacy and safety, ultimately contributing to the creation of innovative therapies that improve patients' quality of life. Enzymlogic aims to become a key resource for organizations focused on successful drug discovery, ensuring their clients achieve optimal returns on investment while advancing therapeutic solutions.

CLOVER Bioanalytical Software is a bioinformatics company specialized in data processing for Bioanalytical Chemistry and Microbial ID and other clinical diagnostics applications using mass spectrometry. Formed by a group of Ph.D. graduates with a wide expertise in business and research, it brings a perfect match to develop cutting-edge software and statistical analysis projects in the biomedical field. They are specialized in mass spectrometry, its clinical applications and mass spectrometry imaging. But their expertise cover many more applications, like medical image processing, univariate and multivariate statistical analysis, and Big Data. They are truly customer-oriented, keeping in mind the goals of their clients and the scalability of the systems. They count with experts in biomedicine, chemistry and biotechnology that speak your own language and understands your needs.

Seaweed Solutions AS is a seaweed cultivator and innovator established in 2009, focusing on large-scale ocean farming of seaweed for various applications, including food, feed, pharmaceuticals, and biomaterials. The company has established itself as a leader in European seaweed cultivation, controlling the entire value chain from proprietary seed hatcheries to processing plants. With a patented cultivation technology called Seaweed Carrier, Seaweed Solutions combines extensive knowledge in marine biology and engineering to pioneer modern seaweed farming practices. Its primary operations are based in Norway, where it manages the largest seaweed farms in Europe dedicated to brown macroalgae. The company's objectives include becoming the leading supplier of cultivated biological seaweed and seaweed seeds in Europe. Additionally, Seaweed Solutions forms partnerships and offers turnkey solutions related to cultivation technology, raw material sourcing, market development, and environmental services, thereby supporting sustainable practices in the seaweed industry.

RemAb Therapeutics is a developer of polymeric glycoconjugates molecule designed to remove antibodies and treat nosocomial infections. The company's technology aims to develop polymeric glycoconjugates to eliminate non-neutralizing natural antibodies that interfere with the natural response of the immune system and favor pathogen growth, providing patients with a new way of treating and preventing various pathologies.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Cyclomics is a Dutch startup focused on revolutionizing cancer care through its proprietary circulating tumor DNA (ctDNA) detection technology. This innovative approach aims to provide faster and more reliable diagnoses, particularly for monitoring cancer recurrence and treatment responses, addressing critical clinical needs that current imaging methods struggle to meet. Cyclomics has developed a diagnostic kit, CyclomicsSeq, which offers superior performance compared to traditional radiological and physical examinations. The initial application of this technology targets head and neck cancers, where effective monitoring of treatment response and recurrence is vital for improving patient survival rates. By enabling accurate measurements and timely interventions, Cyclomics seeks to significantly enhance cancer diagnostics and patient outcomes.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. They use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products.

Mercurna is a developer of life-changing mRNA medicines. They also develop modular nanomedicines that can be adapted to a multitude of diseases with ease. They built a sustainable business that keeps on providing society with truly valuable medicines. They also provide mRNA medicines particularly suited to the treatment of chronic inflammatory diseases.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced tests for cancer assessment and personalized treatment. The company offers a range of products including ConfirmMDx, a prostate cancer testing solution that addresses false-negative biopsy concerns; SelectMDx, which helps guide repeat biopsies for prostate cancer; and AssureMDx, a noninvasive liquid biopsy test for bladder cancer that assists in decision-making for cystoscopy. Additionally, MDxHealth provides PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Founded in 2003 and headquartered in Irvine, California, MDxHealth operates additional offices in Herstal, Belgium, and Nijmegen, the Netherlands. The company generates revenue through clinical laboratory services and the out-licensing of its patented DNA methylation platform and biomarkers, serving markets in the United States and Europe.

DELMIC specializes in correlative light and electron microscopy technology, focusing on applications in life and materials science research. The company offers a range of services, including cathodoluminescence, automated cryo-electron tomography workflows, and efficient electron microscopy solutions. These services are designed to enhance research capabilities by providing reliable and high-throughput methodologies, enabling researchers and organizations to gain insights more quickly and effectively. Through its innovative tools and integrated microscopy approaches, DELMIC aims to facilitate advancements in scientific research.

NG Biotechnology is a biotechnology company established with long-term investments with the partnership structure of academicians who produce microbial cultures with years of experience in environmental biotechnologies and have worked on environmental and agricultural microbiology in established institutions abroad for many years.

Bioengineering Laboratories (BEL) has been conceived as a young, streamlined and multi-faceted organization able to provide technical knowledge and a twenty year experience in designing, testing and producing innovative medical devices in the bioengineering industry. BEL is a pool of professional professionals able to critically address and re-elaborate the key aspects of a “modern” design in the medical field. The knowledge of the market, the openness to new clinical and surgical techniques, the curiosity towards new technologies, the application of an effective Quality System and the constant updating of the current legislative and regulatory requirements are their basis for engineering dedicated to life.

Iris.ai offers an AI-powered science assistant designed to enhance the efficiency of research and development departments by facilitating the navigation of scientific literature. Its primary product, RSpace, features advanced search capabilities, smart filters, reading list analysis, auto-generated summaries, and automated data extraction, enabling users to systematically organize information. By leveraging natural language processing algorithms, Iris.ai addresses the challenges of factuality tracking in AI, providing tools that enhance the accuracy and reliability of scientific research. This platform is aimed at both corporate R&D teams and academic researchers, allowing them to uncover new scientific insights that go beyond traditional human capabilities.

Depixus is a biotechnology company that has developed a novel technology designed for real-time analysis of individual biomolecular interactions at a large scale. Its platform enables comprehensive genome analysis, allowing researchers to examine entire genomic regions quickly and efficiently. This integrated system provides the flexibility to specify the desired level of sequence and epigenetic detail, facilitating the discovery of new biological pathways and the decoding of disease mechanisms. By enhancing the understanding of these processes, Depixus aims to contribute to the development of new precision medicines. The company's focus on advanced DNA and RNA sequencing technologies addresses the limitations of current methods, particularly in achieving single-molecule precision.

omicX decided to harness the exponentially growing collective intelligence in bioinformatics and to leverage it to exploit biological Big Data for novel applications in biotechnology, life science, medecine, agriculture and industry. Their fast-growing company has become a trusted leader and global reference in bioinformatics with users from world leading universities, medical institutions, pharmaceutical companies and the biotech industry.

RegStem is an early stage biopharmaceutical company repurposing molecules and creating new treatments in the fields of regenerative medicine and more specifically in the areas of rare muscle and blood diseases with high unmet medical needs.

AcouSort is a Swedish company specializing in the development and sale of laboratory products and integrated solutions that utilize ultrasound technology for the separation, washing, and enrichment of biological samples. Its offerings cater to researchers and life science companies, focusing on the automated preparation of samples such as blood cells, bacteria, and extracellular vesicles. The technology is rooted in acoustofluidics research from the esteemed group led by Professor Thomas Laurell at Lund University's Department of Biomedical Engineering. Key products include AcouTrap, AcouWash, and AcouPlasma, which facilitate efficient handling of microscopic particles in microfluidic channels for research and diagnostic applications.

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Biodentify was founded as a spin out from Dutch R&D group TNO, in December 2014. TNO is a 3000+ R&D organization, hosting the largest Microbiological research group in the Netherlands. It is owned and managed by JOA Ventures, 3 partners with extensive entrepreneurial experience bringing innovative technologies to market in the Oil & Gas industry. The company has developed a novel technology, predicting prospectivity before drilling, with approx. 70% accuracy, based on microbiological DNA analysis of shallow soil or seabed samples.

Biprocel is a biotechnological company.

Cellink is a biotechnology company and one of the first bioink companies in the world. The company leverages its bioink and 3D printing technology to print human organs and tissue models, which potentially can be used in e.g. oncology research, drug testing, and cosmetic testing. The company’s vision is to create the future of medicine by making bioprinting technology as accessible, user-friendly, and high performing as possible. Cellink has offices in Gothenburg, Sweden, and Palo Alto, California, and collaborates with different organizations across the globe.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Oxoprobics microplates provide a powerful tool and biological services based on this technology for obtaining proof of mechanism data, useful as first exploratory assessments, refocusing and adapting new tailored methodologies for its use in cell biology (e.g. mitochondrial inhibition or uncoupling, stimulation or inhibition of oxygen-consuming reactions catalyzed by enzymes, antibiotic resistance, etc.) or Immunology (lymphoproliferation kinetics in whole blood, antigen recognition and sensitivity, etc.).

KerLine is an innovative start-up and a spin-off company of the Institute of Organic Synthesis and Photoreactivity (ISOF) of the Italian National Research Council (CNR) in Bologna. KerLine founders have developed an outstanding experience in full-length keratin manufacturing and engineering. In particular, they set up a method for the chemical extraction of high molecular weight keratin from natural waste of agrifood and textile industries. The unique properties of the extracted keratin allow its application in different technological fields. The company is located within the Bologna CNR research area.

React4life is an Italian biotech company established in 2016 by Silvia Scaglione and Maurizio Aiello, following over 15 years of research and development. The company focuses on advancing biomedical research through its innovative technology, MIVO® (Multi In Vitro Organ), which represents a next-generation organ-on-a-chip system. This microphysiological platform allows researchers to simulate human biology more accurately in laboratory settings, addressing the limitations of traditional in vitro assays and animal testing. React4life's technology enhances the reliability and predictivity of various applications, including pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals. By enabling the cultivation of three-dimensional human-like tissues for in vitro testing, React4life aims to improve the effectiveness of laboratory experiments and promote ethical research practices.

ReproPharm Vet is a biotechnology company focused on improving livestock breeding through sustainable agricultural practices. It develops user-friendly tools aimed at enhancing the management of livestock breeding while addressing key factors such as economic competitiveness, workload reduction, environmental protection, and animal welfare. ReproPharm's products serve a diverse range of professionals in the industry, including farmers, scientists, artificial insemination technicians, and veterinarians, and are designed for use both on farms and in laboratories. The company's commitment to innovation ensures that it meets the evolving demands of consumers and the livestock breeding market, facilitating efficient and responsible breeding practices.

Inpharmatis offers comprehensive regulatory affairs services to Life Science Industry including Drug Development and Vigilance Services to pharmaceutical, medical device, food supplements, cosmetic and biotech companies. Their area of expertise lies in the European & CIS market. A multi-disciplinary team of qualified regulatory affairs consultants is at your disposal for all aspects of your marketing authorisation applications for active substances and human medicinal products. Inpharmatis shall provide full regulatory support over the whole life cycle of your product.

AXO Science is dedicated to enhancing public health through the development of innovative diagnostic solutions. The company has created a forensic testing tool that offers multi-parameter diagnostic characterizations. This sophisticated tool features an integrated biochip, which incorporates multiple oligonucleotide probes grafted onto a polymer membrane. As a result, forensic departments and diagnostic enterprises can utilize advanced technologies for molecular-based diagnosis, improving their capabilities in the field of diagnostics.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.

CytaCoat is developing a new technology of antibacterial coating for medical devices. CytaCoat AB is a private Swedish company located in the Karolinska Institutet Science Park AB in Solna (Stockholm area). The company was founded by a group of researchers from the Karolinska Institute, one of the foremost medical universities in the world, and the Royal Institute of Technology (KTH). It was a special purpose vehicle started with a goal to develop a new technology of antibacterial coating for medical devices. It was based on a discovery that their proprietary polymer surface exhibits a clear effect on several of the most problematic pathogenic bacteria that pose problems in healthcare today. Since then, the company has been focused on transforming this innovation into a fully viable commercial product and make it available through licenses. CytaCoat has a fully equipped laboratory in the Karolinska Institutet Science Park, where both microbiology evaluation, optimisation of the CytaCoat technology and a pilot plant production can be performed. The company has also established contacts with clinical collaborators at Karolinska University Hospital Neonatal Unit and the Division of Clinical Microbiology. CytaCoat has also been cooperating with experienced consultants in regulatory, clinical research organisations, patent experts and providers of specialist analyses.

BioBlocks is a collaborative medicinal chemistry research organization focused on drug discovery from initial lead discovery through identification of development candidates. They believe that collaboration empowers scientists to achieve more than any single entity or individual could alone. They join forces with their clients to discover compounds qualified for advancement to phase two clinical trials.

Senolytic Therapeutics is a operator of a pharmaceutical company intended to develop medicines and therapeutics for patients affected by age-related diseases. The company's medicines target and eliminate damaged cells, enabling healthcare providers to improve the lives of those affected by diseases associated with aging.

Prasinotech is a trading and biotechnology company delivering healthy and natural ingredients for use in cosmetic, food and pharmaceutical products Prasinotech focuses primarily on producing polysaccharide products from natural marine sources. Being the first company in the world to specialise in polysaccharide products derived from microalgae, Prasinotech takes a leading position in what we believe will be the future in sustainable production of natural ingredients.

LifeTag is a Portuguese technology startup that specializes in the research and development of non-invasive diagnostic technologies aimed at evaluating metabolism and diagnosing various high-incidence metabolic diseases, such as diabetes, obesity, and metabolic syndrome. The company has developed a diagnostic marker that facilitates non-invasive health monitoring, particularly focusing on intestinal permeability to enhance the accuracy of chronic metabolic disease diagnoses. By providing healthcare professionals with effective tools to assess patients without causing discomfort or side effects, LifeTag aims to improve health outcomes and streamline the diagnostic process.

Bioaxial specializes in advanced technology for super-resolved fluorescence microscopy, allowing for the extended imaging of live cells with a resolution below 100 nanometers. The company manufactures optical modules that serve as add-ons for existing commercial microscopes, enhancing their imaging capabilities. Bioaxial's innovative fluorescence microscopy workflow utilizes a beam shaper to create localized light patterns, which minimizes photo-toxicity and photo-bleaching during the scanning of biological samples. This technology is designed to provide clinicians and physicists with improved resolution for live cell imaging. Bioaxial has also filed four patents and secured a fifth, all of which are exclusively owned by the company.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Biomode is a Portuguese startup located in Caldas das Taipas that specializes in developing rapid and accurate molecular diagnostic tests for identifying pathogens within the food, environmental, and life sciences sectors. Utilizing Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA-FISH) technology, Biomode's diagnostic kits provide a streamlined approach that eliminates the need for DNA extraction or amplification, ensuring reliability in the presence of inhibitory compounds and focusing solely on viable bacterial cells. The company plans to launch its first product, Probe4Salmonella®, for detecting Salmonella in food samples, followed by additional kits for Listeria monocytogenes and E. coli O157:H7. In the clinical diagnostics realm, Biomode has developed Probe4Pylori®, which is designed for the rapid identification of clarithromycin-resistant Helicobacter pylori strains and is currently seeking investigational device exemption from the FDA to commence field trials. Founded by researchers from the universities of Minho and Porto, Biomode aims to enhance pathogen detection in both food safety and health diagnostics.

BioCopy developed an innovative, patented technique to copy biomolecules analogous to a photocopier.

BunyaVax exploits proprietary vaccine platform technology to develop safe and efficacious vaccines against infectious diseases and cancer. The unique ‘Plug and Play’ platforms are used to generate potent vaccines that can encode almost any antigen of interest. Applications are in the veterinary and human setting.

SunRegen is a biopharmaceutical company with a mission to develop drugs to treat neurodegenerative diseases. They focus on innovative treatments for patients suffering from neurological, neuromuscular and ophthalmic diseases. Their first product candidates in development target primary optical atrophy. They are further evaluating them for use in serious neurological / neuromuscular diseases such as ALS, Huntington's, Alzheimer’s and Parkinson’s disease. Their team is composed of passionate and innovative founders and experts who have solid track records in drug development and clinical research in multinational pharmaceutical companies or management experience in international technology enterprises. Their determination in bringing life-changing treatments to patients encompasses everything they do.

Pharmaceutical Biotechnology focuses on the development and implementation of new biotech projects with high market potential. They develop, research, and manufacture biotech products with a focus on food, pharmaceutical, hygienic, cosmetic, and environmental applications.

Avectas is a cell engineering technology company, enabling drug developers to manufacture potent engineered cell therapies at therapeutic volumes, with high efficiency and with minimal cell disruption. Avectas technology delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of cell types including T cells for immuno-oncology applications. Unlike the current industry standard of vector-free delivery methods, cells engineered with Avectas technology require no recovery time, leading to a shorter, simpler, more cost effective process.

Tethis is a developer of a smart diagnostic device designed to create a diversified range of potential applications in diagnostic, therapeutic, and drug discovery. It also provides tools to support personalized medicine and targeted therapy in clinical settings.

WellGenetics was founded in July 2014. WellGenetics is dedicated to providing researchers professional services in generating transgenes and gene knockout/knockin in fly and mosquito models. They are an independent company from any academic research institutes. With strong and solid background in Drosophila genetics, their team are composed of experts in molecular biology and in microinjection for generating variety of genetic tools, such as gene deletion, point mutation, gene reporters, tag knockin and RMCE knockin with/without selection marker to level-up your research quality. Each project will be designed, executed, and supervised by postdoctoral scientists, thus to ensure the quality and reliability of entire experiment process.

Leukos Biotech is a biopharmaceutical company established in 2015 as a spin-off from the Josep Carreras Leukaemia Research Institute. The company focuses on developing innovative treatments for Acute Myeloid Leukaemia (AML) and other blood cancers. It specializes in identifying new therapeutic targets against leukemic stem cells in AML, utilizing repurposed small molecules to improve diagnosis and prognosis for patients. Leukos Biotech benefits from strong scientific and financial support from the Josep Carreras Leukaemia Research Institute and the Josep Carreras Leukaemia Foundation, among other collaborators, enhancing its capacity to address critical health challenges associated with haematological malignancies.

Gradientech AB is a biotech company based in Uppsala, Sweden, specializing in the development and supply of microfluidic products for analyzing cell migration and behavior in response to signaling gradients. The company offers a range of CellDirector products designed for research applications, including the CellDirector Opal and CellDirector Ruby, which facilitate studies on endothelial cell migration, angiogenesis, and tumor cell behavior. Additionally, Gradientech provides complementary tools such as Gradient Marker solutions for visualizing gradient formation, a syringe pump for precise fluid delivery, and a vacuum pump for conducting experiments at elevated temperatures. The company also features the QuickMIC® system for ultra-rapid antibiotic susceptibility testing, which enhances the capabilities of microbiology labs by delivering reliable minimum inhibitory concentration results swiftly. Gradientech serves scientists across academic, pharmaceutical, and diagnostic markets globally, and its products are available for purchase online. The company was incorporated in 2009.

PharmaBiome is specialized in the isolation, characterization, and technology of novel intestinal microbes. Their technology platform optimizes the lean and efficient development and production of defined, function-based microbiome therapies to treat intestinal diseases. PharmaBiome’s proprietary development pipeline allows a fast translation from the identification of mode of action to a product ready for clinics, using tailored, ecologically sound bacterial mixtures.

Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis. Lyme diagnostics is primarily focused on the more exact, routine diagnostics of Lyme disease, building on the innovative technologies developed by the diagnostic & therapeutic workgroup of the Lyme Borreliosis Foundation. We offer the results of 30 years of work by 8 medical professionals. Currently, our novel diagnostic methods are supplemented with laboratory-standard, widely-accepted diagnostic procedures, and carefully confirmed by clinical diagnosis. The company's objective is that - after clinical testing - we will be able to offer one single screening method across Europe, and in North America.

Lisapharma S.p.A., founded in 1925 and based in Erba, Italy, specializes in the manufacture of sterile injectable drugs, non-sterile liquids, semisolids, medical devices, and veterinary products. Operating in over 40 countries, the company plays a significant role in the global pharmaceutical market. Lisapharma's manufacturing facility adheres to Good Manufacturing Practice (GMP) standards, ensuring compliance in both domestic and international markets. The company holds various Marketing Authorizations for its internally produced products and also serves as a contract manufacturer for both Italian and multinational clients. In 2019, Lisapharma became a subsidiary of Shandong Sito Bio-technology Co., Ltd., following its acquisition by Italian private equity funds in 2015.

Braingineering Technologies is an innovative biotech company that provides pharmaceutical companies with drug screening services in drug discovery and pre-clinical testing for Parkinson’s disease. Braingineering Technologies offers a new high-tech in vitro Brain-on-a-Chip technology and brain organoid technology that increases efficiency and relevance in the drug development process. Both technologies are based on the utilization of disease specific human induced pluripotent stem cells.

HAWK Biosystems specializes in cancer diagnostics through a companion diagnostics platform that identifies post-translational modifications and protein-protein interactions in pathology samples. The platform quantifies these interactions in single-cell and fixed tissue samples, maintaining the integrity and heterogeneity of the tissue. This technology offers medical practitioners and pharmaceutical companies a novel approach to treatment decisions, particularly in cancer, inflammation, and immune disorders. HAWK Biosystems aims to enhance precision medicine by enabling targeted therapies that match patients with the treatments most likely to be effective, thereby improving patient outcomes, quality of life, and reducing overall drug costs. The company seeks to establish collaborative opportunities within the European health system to further its impact in the field.

InfiCure Bio is a life science company based in Umeå, Sweden, specializing in the preclinical development and validation of drugs aimed at chronic inflammatory and fibrotic conditions. Founded in 2015, it evolved from a project initiated at the Umeå Biotech Incubator by Prof. Dan Holmberg and Dr. Sofia Mayans, leveraging research from their academic work. The company provides a unique preclinical model that simulates the development of fibrosis in various organs, such as the liver and kidneys, which is often preceded by chronic inflammation. This model allows pharmaceutical companies to test their anti-inflammatory and anti-fibrotic drugs comprehensively. InfiCure Bio's services include the setup, execution, analysis, and reporting of results from these effect tests, thereby supporting the development of therapies for significant medical conditions like chronic liver and kidney diseases.

ISS BioSense operates in the field of biotechnology as applied to biosensors. ISS BioSense is a new high-tech SME located in Naples, Italy. The company was born on the initiative of a group of young scientists that decided to apply the expertise acquired in research institutions to biosensors design and development. For the advancement of its projects, ISS BioSense operates in synergy with national and international Research Institutions as well as with private enterprises. The main cultural and technological assets of ISS BioSense are its knowledge and expertise about the use and the manipulation of molecules of biological origin to develop highly specific and sensitive sensors.

Ilya Pharma is a pharmaceutical company focused on developing next-generation biological drugs aimed at enhancing wound healing in skin and mucosa. Founded in 2016 as a spin-out from Uppsala University and the Swedish University of Agriculture, the company employs a unique technique that genetically modifies lactic acid bacteria, commonly found in yogurt. These engineered bacteria serve as vectors to produce and deliver healing substances directly to wounds or within the gastrointestinal tract. This innovative approach is designed to provide accelerated healing for patients, particularly those with diabetes, while maintaining cost-effectiveness.

SymCel is a manufacturer of scientific instruments that specializes in providing innovative tools for real-time cellular bioenergetic measurements. The company develops and markets a label-free assay technology that enables continuous monitoring of cell metabolism and biological activity, including the heat produced by living cells. This technology addresses a critical gap in the field of cell biological research and development, catering to both R&D departments in the life sciences industry and academic research laboratories. By offering a fast and accurate method for data collection, SymCel’s instruments empower researchers and clinicians to uncover new insights into cellular processes, enhancing the understanding of metabolism and its implications in various biological contexts.

EBERS Medical Technology SL is devoted to the development of equipment for cell and tissue culture. They are focused in creating new and innovative products which help the users to improve their protocols by providing new tools able to simplify research tasks or offering technical solutions which make easier to develop new experimental set-ups in simple and efficient way. EBERS manufactures, markets and service products for research institutions in several countries by means of its distributors network and also provides extensive development services of bespoke culture chambers for tissue engineering.

GeneFirst is a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalized medicine. GeneFirst offers robust easy-to-use, sensitive, and affordable molecular diagnostics technologies and products to researchers, clinicians, and drug companies to enable accurate diagnosis and the delivery of safe and effective medicines. Its patented technologies allow for simultaneous detection of multiple targets in one reaction.

Gnubiotics Sciences SA specializes in developing microbiome-modulating products aimed at nurturing, maintaining, and restoring microbiome diversity in humans and animals. Founded in 2016 and based in Epalinges, Switzerland, the company produces glycans and functional mimics of Human Milk Oligosaccharides (HMOs) for the consumer health market. Their flagship product, AMObiomeTM, is designed to enhance microbiome diversity and promote lifelong gut health. By replicating the natural structures found in breast milk, Gnubiotics aims to prevent infections and combat diet-induced obesity, while also addressing the growing demand for healthier food options. The company's innovative approach focuses on supporting immune systems and overall well-being through natural microbiome modulation.

Valitacell develops biotechnology which allows companies to manufacture bio-therapeutic drugs faster and cheaper. Valitacell products allow users to select cells with greater regulatory confidence at the earliest possible stage during the drug development pathway. Valitacell is transforming the Cell Line Development process with simple, robust technologies.

Setenta e Três Mil e Cem is a Portuguese company, funded in 2006 which is specialized in biotechnology and the development of products for the cosmetic and pharmaceutical industries.

Ikan Biotech SL, based in Noáin, Spain, specializes in the development of innovative enzybiotics and preclinical services utilizing zebrafish models. Founded in 2015, the company provides a unique platform that allows for the creation of tumor models, enabling the healthcare industry to design and assess the efficacy of potential cancer treatments. Ikan Biotech's zebrafish models facilitate the microinjection of tumor cells, which helps researchers evaluate the safety and identify potential adverse effects of drug candidates during the early stages of development. The company's services cater to a variety of sectors, including pharmaceuticals, biotechnology, environmental science, and nutraceuticals, among others.

EOS S.r.l. (Effective Optical Systems, www.eosinstruments.com) delivers a new generation of scientific instruments and technological solutions for the classification and characterization of particles and particle mixtures in biological, industrial and environmental heterogeneous fluids. Implementing strategies for particle analysis in complex fluids via light scattering, EOS provides CLASSIZER™ cutting edge family of platforms for the multiparameter analysis at single particle level via the key enabling SPES (Single Particle Extinction and Scattering) patented technology. CLASSIZER™ devices classify single particles on the basis of their optical properties in liquids and aerosols: discriminates particles in heterogeneous samples; enables advanced product formulation by monitoring the particle stability and behaviour in real complex fluids (aggregation, degradation, wetting); boosts QC operations measuring even in presence of impurities, synthesis residues, bubbles and immiscible liquid droplets (typically no filtration or purification is required). CLASSIZER™ platforms are powerful solutions for product R&D and Quality Controls in life sciences, pharmaceuticals, cosmetics, food and beverages, inks and pigments, agrochemicals, lubricants and abrasives and environmental sciences.

Mcule.com: online drug discovery platform for pharma and biotech companies. Mcule.com provides an easy-to-use web interface integrating all the necessary steps in drug discovery. Molecular modeling and compound delivery components for hit identification and lead optimization are already implemented. Bioassay database is currently being set up. Vision: Speed up the drug discovery process tremendously by providing the ultimate drug discovery platform supporting the whole drug discovery process.

Abbelight specializes in super-resolution microscopy and membrane imaging, focusing on single molecule localization microscopy to enhance biological research. The company integrates consumables, hardware, and software to deliver advanced scientific solutions, allowing researchers in biology, pharmacology, and environmental studies to utilize super-resolved fluorescence microscopy for improved observation of biological samples. Abbelight aims to democratize access to these sophisticated techniques by simplifying their application while maintaining high performance standards. To support scientists throughout the research process, Abbelight offers expertise in sample preparation and result analysis, providing a comprehensive approach that combines chemistry, computer science, and optical instruments.

Xtrem Biotech is a technology-based company that develops, produces and markets biostimulants and pesticides of biological origin to offer respectful solutions that are compatible with the environment. Xtrem Biotech has an exclusive collection of microorganisms and a production plant for the cultivation, formulation, and packaging of plant bio-stimulants.

SynVaccine Ltd. is a biotechnology company based in Tel Aviv, Israel, focused on developing preventive viral vaccines targeting major human pathogens. Founded in 2013 by Tuval Ben Yehezkel, the company utilizes innovative technologies that facilitate the computational design of viral genomes and the physical editing of viral vaccine genome libraries. This approach enables SynVaccine to create effective vaccine candidates aimed at addressing significant health challenges posed by viral infections.

ZeClinics is a Start-up biotech offering an outsourcing solution for safety and efficacy screenings of novel chemical molecules using zebrafish.

SenzaGen AB is a biotechnology company based in Lund, Sweden, specializing in in vitro genomic allergen rapid detection (GARD) sensitization tests. Founded in 2010 as a spin-out from Lund University, SenzaGen provides animal-free testing solutions for the cosmetic, pharmaceutical, and chemical industries, focusing on immunotoxicological assays. Its proprietary product line includes GARDskin, which predicts chemical sensitization, GARDpotency, which classifies sensitizers based on genomic biomarkers, and GARDair, an assay for respiratory sensitizers. The company operates through its own laboratory and collaborates with licensed contract research organizations to deliver its services. SenzaGen also engages in partnerships, such as its collaboration with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company serves multiple market segments, including cosmetics, chemicals, medical devices, pharmaceuticals, and food additives, with a significant portion of its business derived from the pharmaceutical sector.

Sequentia Biotech was founded in 2013 by Walter Sanseverino (CEO) and Riccardo Aiese Cigliano (CSO), two young researchers with a real passion for genetics and omics sciences, and is based at the UAB Research Park. Sequentia is a bioinformatics company that offers services and tools that transform genomic data into knowledge in academic research, plant and animal breeding and biomedicine. In just four years, Sequentia has achieved a large highly diversified portfolio of clients and partners, consisting of over 30 public and private research centers, companies and hospitals. The company is taking part in more than 160 R & D public and private projects, and it has two open source biodata banks; and an award-winning R&D line, Tricopharming, which was established in 2014. Cofounders Walter Sanseverino and Riccardo Aiese have published more than 40 scientific articles in high impact journals such as Nature Genetics, Scientific Report or DNA Research.

Founded in 2010, Mediplasma s.r.l., has a strong dedication to the ophthalmology, medical devices and endoprosthesissectors, in order to implement its chemical-physical, clinical and commercial characteristics with innovative treatments. Plasma processes are used to modify the surface properties of materials in biomedical interest to obtain the best compatibility with proteins, cells and biological tissues in vitro or in vivo, applicated in fields of biomaterials, tissue engineering, biosensors, and of bio-reactors.

DC4U is a life science company focused on developing technologies that modulate the human immune response, particularly through the immunological application of glycobiology. The company's proprietary platform technology, GlycoDC, is designed to influence immune system activity by targeting dendritic cells with glycan-modified antigen conjugates. This innovative approach allows for the development of therapeutics aimed at treating allergies and autoimmune diseases by either enhancing or suppressing immune responses. Through its research and technological advancements, DC4U aims to provide solutions that enable individuals to manage their health effectively and improve their quality of life.

GENIS is a biotechnology company headquartered in Siglufjörður, Iceland. They strive to discover, develop and commercialize novel and life-changing products, supplements and medical devices derived from crustacean exoskeletons. The GENIS team has been developing cutting-edge research on the production of chitin, chitosan, and short chain chitosan for two decades. Their mission is to leverage this accumulated body of world-class scientific research with the intent of providing life-altering benefits for individuals.

TychoBio operates on the development of plant biotechnology to sustainably produce high value natural products using engineered moss grown in photosynthetic bioreactors. Mosses are small flowerless plants that typically grow in dense green clumps or mats, often in damp or shady locations. TychoBio applies powerful tools from synthetic biology to commercialize moss as a specialized production platform for high-value compounds. For news please visit

Planet is solving complex human problems learning from forms, processes and (eco)systems in Nature. Planet is a start-up founded by Alessandro Villa and Alessandro Bianciardi in 2013. Although different expertise and professional background, both of them are into biology, complex biology systems and bio-inspired technology and after they have concluded a specific educational programme (respectively Biomimicry Specialist Program and Biomimicry Professional Program) in Biomimicry Institute (San Francisco, USA), they decided to set up an entrepreneurial business with the main goal to apply and share that innovative discipline learnt in USA. Planet is ideed specialized in biologically inspired design for sustainable innovation Planet is part of the international network linked to the Biomimicry 3.8 Institute. Planet can count on a world-wide network of professionals in different disciplines (biology, engineering, design, economy, business management, architecture, chemistry and more) and experienced in the Biomimicry Thinking framework. Planet is also founder both of Biomimicry Italy and European Biomimicry Alliance

Metafora Biosystems is a biotechnology company focused on developing receptor binding domains (RBDs), which are innovative ligands targeting nutrient transporters. Their technology enables the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. This capability positions Metafora's tools as competitive assets in various segments of the biomarker market, offering unique insights into cellular responses and enhancing understanding of metabolic processes.

HONGO`S BIOFACTORY is a company specialized in the cultivation of mushrooms and edible and medicinal mushrooms. It offers technical advice and specialized training in all aspects related to the cultivation, preparation of substrates and mycelium for fungi or mushrooms. The company was formed in 2008 and is based in Calahorra, Spain.

Betalin Therapeutics is a privately-held company. We develop a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP). The EMP is a combination of harvested pancreatic islets (also known as Islets of Langerhans) and a proprietary biological micro-environment for supporting the harvested cells. After promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics is currently putting efforts to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials.

Nano4 provides solutions for rapid colorimetric identification of molecular targets of disease (DNA/RNA) at point-of-care (PoC). NANO4 Global is a startup launched in 2015 to market nanotechnology based molecular diagnostics. The NANO4 is a nanodiagnostics platform that provides simple colorimetric detection of DNA and RNA with single base selectivity. Following more than 12 years of research in nanodiagnostics at Universidade NOVA de Lisboa - Science and Technology, Department of Lifesciences, this technology was awarded the Scientific Prize - Santander Totta / Universidade NOVA de Lisboa.

Residual Barrier Technology creates environmentally friendly solutions to battle against harmful bacteria and pathogens. Algae, fungi & bacteria killer for all artificial grass and hard surfaces and to sanitise sports surfaces. RBT Concentrate is the ultimate first line of defence against surface contamination from algae and the micro-organisms that create a plethora of surface problems leading to fungal growth, slime and corrosion. It is also highly effective against 99.999% of the dangerous microbes that transmit disease and infections and to sanitise thoroughly. RBT concentrate is deadly to microbes but is perfectly safe for humans and animals. It is non-hazardous to users and has been assessed by the Environmental Agency. However, the microbial biofilm eliminates the persistent problems associated with algal growth across a huge range of applications in various sectors, continuing to work for weeks or months after application.

Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwide understand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues. Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest. Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects.

SiriusXT Limited, based in Dublin, Ireland, specializes in the development and manufacturing of a soft x-ray microscope known as the SXT system. Founded in 2015, the company primarily serves researchers in disease research and drug discovery. The microscope employs a vacuum-based laser-produced plasma light source, enabling high-resolution imaging of the 3D internal structure of cells in their native, fully hydrated state. This technology is akin to a CT scan for cells, allowing for detailed visualization without the need for stains or contrast agents. The SXT system is particularly beneficial for disease researchers, pharmaceutical companies, and biotechnologists, as it facilitates the understanding of disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray microscope, SiriusXT's system can produce full cell 3D tomographs in a matter of minutes, significantly advancing imaging capabilities in scientific research.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.